Tumor growth was better controlled when CAN-2409 treatment was combined with anti–CTLA-4 antibody therapy compared with CAN-2409 + prodrug treatment alone (Fig. 7A and B; Supplementary Fig. S3A). This evidence concerns the gene CTLA4 and neoplasm.